Managing Anemia & Bone Disease in CKD: Insights by Dr. Sandip Kumar Bhattacharya | EKDG

In this session from CKD Update 2024, Dr. Sandip Kumar Bhattacharya discusses the pathophysiology and management of anemia and bone mineral disease in chronic kidney disease (CKD). He explains how these conditions contribute to increased morbidity and mortality in CKD patients, highlighting the role of erythropoiesis-stimulating agents (ESAs), iron supplementation, and phosphate binders. Dr. Bhattacharya also delves into newer therapies like hypoxia-inducible factor (HIF) stabilizers and their potential in improving patient outcomes.

Key points covered:

The role of anemia and bone mineral disease in CKD progression
Pathophysiology of anemia in CKD: impaired erythropoietin production and iron absorption
The impact of bone mineral disorders on cardiovascular health
Advances in anemia management: ESAs, iron supplements, and newer therapies like Roxadustat
Bone mineral disease management: phosphate binders, calcitriol, and calcium regulation
The importance of early detection and management in primary care settings

This video provides essential insights into the management of anemia and bone mineral disorders in CKD patients, crucial for healthcare professionals involved in nephrology, primary care, and geriatric care.

#CKD #Anemia #BoneDisease #DrSandipKumarBhattacharya #IronSupplements #ESAs #HypoxiaInducibleFactor #Roxadustat #KidneyDisease #Nephrology #MedicalEducation #PrimaryCare #PhosphateBinders #Calcitriol #BoneMineralDisorders